| 查看: 1382 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
一志愿北京协和药学专硕310 本科哈尔滨医科大学求调剂
已经有0人回复
-
[求助] 流式死活染 & 单细胞门控设置被质疑，如何优化并解释？
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有100人回复
-
蛋白稳定性实验与功能实验不一致
已经有11人回复
-
第4年了，马上40了，可能我与国基确实无缘吧。。。
已经有12人回复
-
2026年申博药学专业
已经有1人回复
-
药学专硕申博
已经有3人回复
» 抢金币啦！回帖就可以得到:
-
【强推｜可留校】济南大学博士后招聘（水利工程/铁锰碳环境过程）
+1/287
-
中山大学附属医院实验和生信科研助理招聘
+1/79
-
武汉纺织大学全重实验室国家级人才团队先进纤维与功能器件课题组 接收调剂研究生
+1/55
-
艾里卡特 (Alicat) - 燃料电池测试系统与质量流量和压力仪表
+3/49
-
天津城建大学招收物理、化学或者生物调剂生一名，前往天津大学联合培养
+1/38
-
招收2名土木工程方向硕士研究生
+1/37
-
福建农林大学材料院招收调剂硕士生
+1/37
-
赣南师范大学智能制造与未来能源学院2026年硕士调剂信息
+1/16
-
中科院物理所二维材料方向招收推免研究生
+1/13
-
广东唯一石化院校——资源与环境专硕招生
+1/12
-
烟台大学先进陶瓷方向 招收材料专业调剂研究生
+1/11
-
shu湘潭大学化工学院招收化工、能源动力、工程热物理相关研究生调剂
+1/8
-
墨子实验室理论计算和模拟研究组诚聘海内外优秀人才
+1/7
-
双一流天津工业大学电信学院李鸿强教授招收2026年申请审核制博士
+1/5
-
天津大学利物浦福州联合学院中外合办硕士【首批offer已发出】
+1/5
-
南医大基础医学院招收调剂生（2生信1生物））
+1/3
-
中科院科研助理招聘
+1/3
-
26年招收07 08学术型/专业型硕士研究生
+1/3
-
【官方】西京学院2026年硕士研究生招生调剂公告发布，11个专业，A区线上即可
+1/2
-
上海交通大学化学化工学院张智涛课题组诚聘博士后
+1/1
11楼2015-09-14 11:50:36
7楼2015-08-31 16:02:44
9楼2015-09-01 08:14:29
10楼2015-09-01 08:19:15
